The Battle Against Hormone-Refractory Prostate Cancer
Is Satraplatin the Second-Line Savior?
- 5 Downloads
KeywordsProstate Cancer Docetaxel Estramustine Taxotere Pivotal Phase
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- 1.American Cancer Society. Cancer Facts and Figures 2006. Atlanta (GA): American Cancer Society, 2006Google Scholar
- 5.GPC Biotech. Interim analysis news neither necessarily positive or negative. New York: Lehman Brothers Global Equity Research, 2006Google Scholar
- 6.Trials and tribulations in prostate cancer: Xinlay rejected by US FDA committee. Pharm Diagn Innov 2005; 3 (10): 11–3Google Scholar
- 7.GPC Biotech. Operating results — FY 2005 results. New York: Lehman Brothers Global Equity Research, 2006Google Scholar
- 8.GPC Biotech. Change of price target. New York: Lehman Brothers Global Equity Research, 2006Google Scholar
© Adis Data Information BV 2006